The vials dispensed with the Sinovac COVID-19 vaccine are seen as the Thai tourist island of Phuket runs to vaccinate its population amid the outbreak of coronavirus disease (COVID-19), and before the end of July 1. of strict quarantine for overseas visitors, to bring back tourism revenue to Phuket, Thailand, on April 1, 2021. REUTERS / Jorge Silva
Sinovac’s COVID-19 vaccine, CoronaVac, was 67% effective in preventing symptomatic infection in the first study of the Chinese trait, the Chilean government said Friday.
The vaccine was 85% effective in preventing hospitalizations and 80% effective in preventing deaths, the government said in a report by the Chilean health ministry.
The publication of the data makes Chile one of the few countries, including the United Kingdom and Israel, that have used inoculation campaigns to obtain information on vaccine efficacy outside of controlled clinical trials and when faced with unpredictable variables. in societies.
Israel’s actual study on the effectiveness of the Pfizer vaccine (PFE.N) examined the results of 1.2 million people, a mix between those who received the shot and those who did not.
The Chile study examined the effectiveness of CoronaVac among 10.5 million people, looking again at both vaccinated and non-vaccinated people. Vaccines were administered in Chile with an approximate separation of 28 days.
The data compare favorably with previously published data on the efficacy of CoronaVac in clinical trials.
In January, a Brazilian trial said the overall effectiveness of the drug in preventing symptomatic infection was 50.4%. A later study, published this month, said efficacy against symptomatic COVID-19 was 50.7%, efficacy against cases requiring medical treatment was 83.7%, and efficacy against moderate cases. and 100% severe.
Indonesia approved the emergency use of the vaccine based on provisional data showing that it was 65% effective.
In a Turkish trial, CoronaVac had an efficacy in the prevention of symptomatic infections of 83.5% and 100% in the prevention of serious diseases and hospitalization.
The Chilean study examined the impact of vaccination among people in the public health system between February 2 and April 1, adjusting for age, sex, comorbidities, income level, and nationality.
Its authors stressed that its results, for example protection against death lower than in clinical trials, should be considered in the context of a second fierce wave of the pandemic.
We compared people who were not inoculated, individuals 14 days or more after receiving a dose and more than 14 days after receiving a second dose.
The results showed that people who were partially vaccinated, with only one shot, were found to be much more vulnerable to COVID-19 recruitment.
Our standards: the principles of trust of Thomson Reuters.